The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas

Abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of 15 months despite standard care therapy consisting of maximal surgical debulking, followed by radiation therapy with concurrent and adjuvant temozolomide treatment. The natural history of GBM is characterized by inevitable recurrence with patients dying from increasingly resistant tumor regrowth after therapy. Several mechanisms including inter- and intratumoral heterogeneity, the evolution of therapy-resistant clonal subpopulations, reacquisition of stemness in glioblastoma stem cells, multiple drug efflux mechanisms, the tumor-promoting microenvironment, metabolic adaptations, and enhanced repair of drug-induced DNA damage have been implicated in therapy failure. Extracellular vesicles (EVs) have emerged as crucial mediators in the maintenance and establishment of GBM. Multiple seminal studies have uncovered the multi-dynamic role of EVs in the acquisition of drug resistance. Mechanisms include EV-mediated cargo transfer and EVs functioning as drug efflux channels and decoys for antibody-based therapies. In this review, we discuss the various mechanisms of therapy resistance in GBM, highlighting the emerging role of EV-orchestrated drug resistance. Understanding the landscape of GBM resistance is critical in devising novel therapeutic approaches to fight this deadly disease.

Keywords

Glioblastoma / resistance / extracellular vesicles / temozolomide / radiation

References

[1] Wen PY,Lee EQ.Glioblastoma in adults: a society for neuro-oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions..Neuro Oncol2020; PMCID:PMC7594557

[2] Stupp R,van den Bent MJ.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma..Oncol Times2005;27:15-6

[3] Cohen MH.Food and drug administration drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme..Clin Cancer Res2005;11:6767-71

[4] Noch EK,Magge R.Challenges in the treatment of glioblastoma: multisystem mechanisms of therapeutic resistance..World Neurosurg2018;116:505-17

[5] Ralte AM,Karak AK,Sarkar C.Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors..Pathol Oncol Res2001;7:267-78

[6] Sarkar C,Sharma MC.Recurrent astrocytic tumours--a study of p53 immunoreactivity and malignant progression..Br J Neurosurg2002;16:335-42

[7] Mallick S,Hakim A.Management of glioblastoma after recurrence: a changing paradigm..J Egypt Natl Canc Inst2016;28:199-210

[8] Gruber ML.Temozolomide in combination with Irinotecan for treatment of recurrent malignant glioma..Am J Clin Oncol2004;27:33-8

[9] Ricklefs FL,Krenzlin H.Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles..Sci Adv2018;4:eaar2766 PMCID:PMC5842038

[10] Szatanek R,Zimoch J,Siedlar M.The methods of choice for extracellular vesicles (EVs) characterization..Int J Mol Sci2017;18:1153 PMCID:PMC5485977

[11] Kosgodage US,MacLatchy A.Peptidylarginine deiminases post-translationally deiminate prohibitin and modulate extracellular vesicle release and microRNAs in glioblastoma multiforme..Int J Mol Sci2018;20: PMCID:PMC6337164

[12] Yekula A,Muralidharan K,Carter BS.Extracellular vesicles in glioblastoma tumor microenvironment..Front Immunol2019;10:3137 PMCID:PMC6990128

[13] Skog J,van Rijn S.Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers..Nat Cell Biol2008;10:1470-6 PMCID:PMC3423894

[14] Shankar GM,Stott SL,Carter BS.Liquid biopsy for brain tumors..Exp Rev Mol Diagn2017;17:943-7 PMCID:PMC5856481

[15] Bark JM,Chua B,Punyadeera C.Circulating biomarkers in patients with glioblastoma..Br J Cancer2020;122:295-305 PMCID:PMC7000822

[16] Verhaak RGW,Purdom E.Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1..Cancer Cell2010;17:98-110 PMCID:PMC2818769

[17] Louis DN,Reifenberger G.The 2016 world health organization classification of tumors of the central nervous system: a summary..Acta Neuropathol2016;131:803-20

[18] Wang Q,Hu X.Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment..Cancer Cell2017;32:42-56.e6 PMCID:PMC5599156

[19] Young RM,Davis G.Current trends in the surgical management and treatment of adult glioblastoma..Ann Transl Med2015;3:121 PMCID:PMC4481356

[20] Neftel C,Filbin MG.An integrative model of cellular states, plasticity, and genetics for glioblastoma..Cell2019;178:835-49.e21 PMCID:PMC6703186

[21] Kim H,Amini SS.Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution..Genome Res2015;25:316-27 PMCID:PMC4352879

[22] Johnson BE,Hong C.Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma..Science2014;343:189-93 PMCID:PMC3998672

[23] Wang J,Ladewig E.Clonal evolution of glioblastoma under therapy..Nat Genet2016;48:768-76 PMCID:PMC5627776

[24] Mazor T,Johnson BE.DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors..Cancer Cell2015;28:307-17 PMCID:PMC4573399

[25] Nowell PC.The clonal evolution of tumor cell populations..Science1976;194:23-8

[26] Reinartz R,Kebir S.Functional subclone profiling for prediction of treatment-induced intratumor population shifts and discovery of rational drug combinations in human glioblastoma..Clin Cancer Res2017;23:562-74 PMCID:PMC5241221

[27] Favero F,Salm M.Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome..Ann Oncol2015;26:880-7 PMCID:PMC4405282

[28] Klughammer J,Roetzer T.The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space..Nat Med2018;24:1611-24 PMCID:PMC6181207

[29] Scorsetti M,Pessina F.Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma..BMC Cancer2015;15:486 PMCID:PMC4484625

[30] Singh SK,Clarke ID.Identification of human brain tumour initiating cells..Nature2004;432:396-401

[31] Huang Z,Guryanova OA,Bao S.Cancer stem cells in glioblastoma - molecular signaling and therapeutic targeting..Protein Cell2010;1:638-55 PMCID:PMC4875273

[32] Toda M.Glioma stem cells and immunotherapy for the treatment of malignant gliomas..ISRN Oncology2013;2013:1-13 PMCID:PMC3671309

[33] Calabrese C,Kocak M.A perivascular niche for brain tumor stem cells..Cancer Cell2007;11:69-82

[34] Meyer M,Lan X.Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity..Proc Natl Acad Sci U S A2015;112:851-6 PMCID:PMC4311802

[35] Qazi MA,Venugopal C.A novel stem cell culture model of recurrent glioblastoma..J Neurooncol2016;126:57-67

[36] Huang Q,Dong J.Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro..BMC Cancer2008;8:304 PMCID:PMC2584338

[37] Jackson M,Nowak A.Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target..Carcinogenesis2015;36:177-85

[38] Chen J,Yu TS.A restricted cell population propagates glioblastoma growth after chemotherapy..Nature2012;488:522-6 PMCID:PMC3427400

[39] Liu G,Zeng Z.Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma..Mol Cancer2006;5:67 PMCID:PMC1697823

[40] Bao S,McLendon RE.Glioma stem cells promote radioresistance by preferential activation of the DNA damage response..Nature2006;444:756-60

[41] Osuka S,Shimizu T.IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells..Stem Cells2013;31:627-40

[42] Osuka S.Overcoming therapeutic resistance in glioblastoma: the way forward..J Clin Invest2017;127:415-26 PMCID:PMC5272196

[43] Andersson ER.Therapeutic modulation of Notch signalling - are we there yet?.Nat Rev Drug Discov2014;13:357-78

[44] Pandit R,Götz J.The blood-brain barrier: physiology and strategies for drug delivery..Adv Drug Deliv Rev2019;

[45] Arvanitis CD,Jain RK.The blood-brain barrier and blood-tumour barrier in brain tumours and metastases..Nat Rev Cancer2020;20:26-41

[46] Salaroglio IC,Rolando B.Validation of thiosemicarbazone compounds as P-glycoprotein inhibitors in human primary brain-blood barrier and glioblastoma stem cells..Mol Pharm2019;16:3361-73

[47] Haar CP,Wallace GC4th.Drug resistance in glioblastoma: a mini review..Neurochem Res2012;37:1192-200 PMCID:PMC4518733

[48] Agarwal S,Elmquist WF.Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up..Curr Pharm Des2011;17:2793-802 PMCID:PMC3269897

[49] Agarwal S,Zellmer DM.Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents..Mol Cancer Ther2012;11:2183-92 PMCID:PMC3469747

[50] Hosokawa Y,Inoue A.Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2..Biochim Biophys Acta2015;1850:1197-205

[51] Becker CM,McFarren SJ.Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma..Neuro Oncol2015;17:1210-9 PMCID:PMC4588756

[52] de Gooijer MC,Buckle T.Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2..Neoplasia2018;20:710-20 PMCID:PMC6030392

[53] Durmus S,Wagenaar E,Schinkel AH.Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar..Mol Pharm2012;9:3236-45

[54] Mason WP.Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma..Neuro Oncol2015;17:1181-2 PMCID:PMC4588763

[55] Broekman ML,Abels ER,Krichevsky AM.Multidimensional communication in the microenvirons of glioblastoma..Nat Rev Neurol2018;14:482-95 PMCID:PMC6425928

[56] McGranahan T,Ahmad S.Current state of immunotherapy for treatment of glioblastoma..Curr Treat Options Oncol2019;20:24 PMCID:PMC6394457

[57] Wolf A,Guha A.Targeting metabolic remodeling in glioblastoma multiforme..Oncotarget2010;1:552-62 PMCID:PMC3035636

[58] Zhou W.Metabolic abnormalities in glioblastoma and metabolic strategies to overcome treatment resistance..Cancers2019;11:1231 PMCID:PMC6770393

[59] Masui K,Ikegami S.Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance..Proc Natl Acad Sci U S A2015;112:9406-11 PMCID:PMC4522814

[60] Schito L.Hypoxia-inducible factors: master regulators of cancer progression..Trends Cancer Res2016;2:758-70

[61] Anderson P,Ivanov P.Stress granules, P-bodies and cancer..Biochim Biophys Acta2015;1849:861-70 PMCID:PMC4457708

[62] Lebelo MT,Visagie MH.Warburg effect and its role in tumourigenesis..Arch Pharm Res2019;42:833-47

[63] Comerford KM,Karhausen J,Montalto MC.Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene..Cancer Res2002;62:3387-94

[64] Vaupel P,Höckel M.Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy..Semin Oncol2001;28:29-35

[65] Spehalski EI,Peters C,Camphausen K.The quiescent metabolic phenotype of glioma stem cells..J Proteomics Bioinform2019;12:96-103 PMCID:PMC7061459

[66] Oliver L,Marhuenda FB,Vallette FM.Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy..Curr Mol Pharmacol2009;2:263-84

[67] Epple LM,Merz AL.Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells..PLoS One2013;8:e73267 PMCID:PMC3748289

[68] Ciccia A.The DNA damage response: making it safe to play with knives..Molecular Cell2010;40:179-204 PMCID:PMC2988877

[69] Caracciolo D,Tagliaferri P.Alternative non-homologous end joining repair: a master regulator of genomic instability in cancer..Precis Cancer Med2019;2:8

[70] Fu D,Samson LD.Balancing repair and tolerance of DNA damage caused by alkylating agents..Nat Rev Cancer2012;12:104-20 PMCID:PMC3586545

[71] Hegi ME,Gorlia T.MGMTGene silencing and benefit from temozolomide in glioblastoma..New Engl J Med2005;352:997-1003

[72] Hunter C,Cahill DP.A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy..Cancer Res2006;66:3987-91 PMCID:PMC7212022

[73] Erasimus H,Niclou S.DNA repair mechanisms and their clinical impact in glioblastoma..Mutat Res Rev Mut Res2016;769:19-35

[74] Lawrence JE,Belton RJ,Winn RJ.Targeting DNA repair mechanisms to treat glioblastoma..Adv DNA Rep2015;

[75] Osswald M,Sahm F.Brain tumour cells interconnect to a functional and resistant network..Nat2015;528:93-8

[76] Namee NM.Extracellular vesicles and anti-cancer drug resistance..Biochim Biophys Acta Rev Cancer2018;1870:123-36

[77] Ning K,Sun X.UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer..J Surg Oncol2017;115:932-40

[78] Bebawy M,Lee E.Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells..Leukemia2009;23:1643-9

[79] Aung T,Vogel D.Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3..Proc Natl Acad Sci U S A2011;108:15336-41 PMCID:PMC3174603

[80] Ma X,He D.Transient receptor potential channel TRPC5 is essential for P-glycoprotein induction in drug-resistant cancer cells..Proc Natl Acad Sci U S A2012;109:16282-7 PMCID:PMC3479621

[81] Yang SJ,Li J.Predictive role of GSTP1-containing exosomes in chemotherapy-resistant breast cancer..Gene2017;623:5-14

[82] Dong H,Chen R.Exosome-mediated transfer of lncRNA SNHG14 promotes trastuzumab chemoresistance in breast cancer..Int J Oncol2018; PMCID:PMC6065402

[83] Jing C,Qin X.Exosome-mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR-21..Oncol Lett2018;15:9811-7 PMCID:PMC6004702

[84] Fu X,Qu S.Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway..J Exp Clin Cancer Res2018;37: PMCID:PMC5846230

[85] Liu T,Sun D.Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma..Acta Biochim Biophys Sin2017;49:808-16

[86] Zhang S,Qu J.Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells..Braz J Med Biol Res2017;51:e6472 PMCID:PMC5685060

[87] Vella LJ,Coleman B,Hill AF.Intercellular resistance to BRAF inhibition can be mediated by extracellular vesicle-associated PDGFRβ..Neoplasia2017;19:932-40 PMCID:PMC5678363

[88] Fornari F,Patrizi C.In hepatocellular carcinoma miR-221 modulates Sorafenib Resistance through Inhibition of caspase-3-mediated apoptosis..Clin Cancer Res2017;23:3953-65

[89] Xu CG,Ren YQ,Wang LQ.Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells..Eur Rev Med Pharmacol Sci2016;20:4362-8

[90] McCubrey JA,Fitzgerald TL.Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis..Adv Biol Regul2015;57:75-101

[91] Zheng P,Wang W.Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional Apolipoprotein E..Cell Death Dis2018;9:434 PMCID:PMC5864742

[92] Qin X,Zhou L.Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner..Int J Nanomedicine2017;12:3721-33 PMCID:PMC5439933

[93] Hu YB,Mu L.Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance..Oncogene2019;38:1951-65 PMCID:PMC6756234

[94] Ozawa PMM,Cavalli IJ,de Souza Fonseca Ribeiro EM.Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells..Breast Cancer Res Treat2018;172:713-23 PMCID:PMC6245099

[95] Fatima F.Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy..Chin J Cancer2015;34:541-53 PMCID:PMC4593342

[96] Lobb RJ,Wiegmans A,Larsen JE.Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance..Int J Cancer2017;141:614-20

[97] Crow J,Banskota S,Schmitt S.Exosomes as mediators of platinum resistance in ovarian cancer..Oncotarget2017;8:11917-36 PMCID:PMC5355315

[98] Santos JC,Sarian LO,Ribeiro ML.Exosome-mediated breast cancer chemoresistance via miR-155 transfer..Sci Rep2018;8:829 PMCID:PMC5770414

[99] Wang M,Yu S.Paclitaxel resistant gastric cancer MGC 803 cells promote epithelial to mesenchymal transition and chemoresistance in paclitaxel sensitive cells via exosomal delivery of miR 155 5p..Int J Oncol2018; PMCID:PMC6254863

[100] Garnier D,Kislinger T.Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization..Neuro Oncol2018;20:236-48 PMCID:PMC5777501

[101] Baulch JE,Tran KK,Zhou Y-H.Irradiation of primary human gliomas triggers dynamic and aggressive survival responses involving microvesicle signaling..Environ Mol Mutagen2016;57:405-15

[102] Zhang Z,Chen Z.Transfer of microRNA via macrophage-derived extracellular vesicles promotes proneural-to-mesenchymal transition in glioma stem cells..Cancer Immunol Res2020;

[103] Yue X,Xia T.Hypoxic glioma cell-secreted exosomal miR-301a activates Wnt/β-catenin signaling and promotes radiation resistance by targeting TCEAL7..Mol Ther2019;27:1939-49 PMCID:PMC6838947

[104] Zeng AL,Liu YW.Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma..Oncogene2017;36:5369-81 PMCID:PMC5611480

[105] Pavlyukov MS,Bastola S.Apoptotic cell-derived extracellular vesicles promote malignancy of glioblastoma via intercellular transfer of splicing factors..Cancer Cell2018;34:119-35.e10 PMCID:PMC6048596

[106] Ramakrishnan V,Akers J.Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas..E Bio Med2020;55:102736 PMCID:PMC7195524

[107] Dai X,Zhuang Z.AHIF promotes glioblastoma progression and radioresistance via exosomes..Int J Oncol2019;54:261-70

[108] André-Grégoire G,Gavard J.Temozolomide affects extracellular vesicles released by glioblastoma cells..Biochimie2018;155:11-5

[109] Yu T,Zhi T.Delivery of MGMT mRNA to glioma cells by reactive astrocyte-derived exosomes confers a temozolomide resistance phenotype..Cancer Lett2018;433:210-20

[110] Shao H,Lee K.Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma..Nat Commun2015;6:6999 PMCID:PMC4430127

[111] Zhang Z,Lu C,Zeng A.Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma..J Exp Clin Cancer Res2019;38:166 PMCID:PMC6469146

[112] Yin J,Zhang Z,Yan W.Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma..E Bio Med2019;42:238-51 PMCID:PMC6491393

[113] Mrowczynski OD,Sundstrom JM.Exosomes impact survival to radiation exposure in cell line models of nervous system cancer..Oncotarget2018;9:36083-101 PMCID:PMC6281426

[114] Munoz JL,Mareedu S.Cycling quiescence in temozolomide resistant glioblastoma cells is partly explained by microRNA-93 and -193-mediated decrease of cyclin D..Front Pharmacol2019;10:134 PMCID:PMC6395452

[115] Richards KE,Fishel ML,Littlepage LE.Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells..Oncogene2017;36:1770-8 PMCID:PMC5366272

[116] Suklabaidya S,Senapati S.Pancreatic fibroblast exosomes regulate survival of cancer cells..Oncogene2017;36:3648-9

[117] Hu Y,Mu L.Fibroblast-derived exosomes contribute to chemoresistance through priming cancer stem cells in colorectal cancer..PLoS One2015;10:e0125625 PMCID:PMC4418721

[118] Yeung CLA,Co NN.Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1..Nat Commun2016;7: PMCID:PMC4820618

[119] Zheng P,Yuan X.Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells..J Exp Clin Cancer Res2017;36:53 PMCID:PMC5390430

[120] Challagundla KB,Neviani P.Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy..J Nat Cancer Inst2015;107:djv135 PMCID:PMC4651042

[121] Chuang HY,Liu HW.Preclinical evidence of STAT3 inhibitor pacritinib overcoming temozolomide resistance via downregulating miR-21-enriched exosomes from M2 glioblastoma-associated macrophages..J Clin Med2019;8:959 PMCID:PMC6678764

[122] Safaei R.Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells..Mol Cancer Ther2005;4:1595-604

[123] Muralidharan-Chari V,Asimakopoulos AG.Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells..Oncotarget2016;7:50365-79 PMCID:PMC5226588

[124] Samuel P,Carter DRF.Mechanisms of drug resistance in cancer: the role of extracellular vesicles..Proteomics2017;17:

[125] Ifergan I,Assaraf YG.Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance..Cancer Res2005;65:10952-8

[126] Ciravolo V,Ghedini GC.Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy..J Cell Physiol2012;227:658-67

[127] Simon T,Schellenberger P.Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma..Mol Cancer2018;17:132 PMCID:PMC6117885

[128] Panagopoulos K,Dillard C.Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure..Mol Cancer2013;12:118 PMCID:PMC3851868

[129] Yuwen DL,Liu J,Shu YQ.MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer..Eur Rev Med Pharmacol Sci2017;21:2650-8

[130] Lv J,Zhou G.Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma..Nat Commun2019;10: PMCID:PMC6718666

[131] Russo A,Gunasekaran M.Liquid biopsy tracking of lung tumor evolutions over time..Expert Rev Mol Diagn2019;19:1099-108

[132] Miller AM,Pentsova EI.Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid..Nature2019;565:654-8 PMCID:PMC6457907

[133] Martinez VG,Salimu J.Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles..Oncoimmunology2017;6:e1362530 PMCID:PMC5706614

[134] Wei F,Zhou T.Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p..Mol Cancer2017;16:132 PMCID:PMC5526308

[135] Zaika AI,Erster SH.ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors..J Exp Med2002;196:765-80 PMCID:PMC2194062

[136] Hou LC,Hsu AR.Recurrent glioblastoma multiforme: a review of natural history and management options..Neurosurg Focus2006;20:E5

[137] Sampson JH,Fecci PE.Brain immunology and immunotherapy in brain tumours..Nat Rev Cancer2020;20:12-25 PMCID:PMC7327710

[138] Qazi MA,Venugopal C.Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma..Ann Oncol2017;28:1448-56

[139] Yong RL,Mihatov N.Residual tumor volume and patient survival following reoperation for recurrent glioblastoma..J Neurosurg2014;121:802-9

[140] Ringel F,Sabel M.Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection..Neuro Oncol2016;18:96-104 PMCID:PMC4677413

[141] Brem H,Burger PC.Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group..Lancet1995;345:1008-12

[142] Robertson CA,Abrahamse H.Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT..J Photochem Photobiol B2009;96:1-8

[143] Elsaie MLT.Photodynamic therapy: new research.2013;Nova Science

[144] Smith CJ,Myers CS.Long-term outcome data from 121 patients treated with Gamma Knife stereotactic radiosurgery as salvage therapy for focally recurrent high-grade gliomas..J Radiosurg SBRT2019;6:199-207 PMCID:PMC6774481

[145] Shrieve DC,Wen PY.Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme..Neurosurgery1995;36:275-82discussion 282-4

[146] Bernstein M,Glen J,Thomason C.Brachytherapy for recurrent malignant astrocytoma..Int J Radiat Oncol Biol Phys1994;30:1213-7

[147] Fogh SE,Glass J.Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas..J Clin Oncol2010;28:3048-53 PMCID:PMC2982785

[148] Ventero MP,Quereda C.Correction: radiotherapy resistance acquisition in glioblastoma. Role of SOCS1 and SOCS3..PLoS One2019;14:e0215714 PMCID:PMC6467407

[149] Friedman HS,Wen PY.Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma..J Clin Oncol2009;27:4733-40

[150] Kreisl TN,Moore K.Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma..J Clin Oncol2009;27:740-5 PMCID:PMC2645088

[151] Raizer JJ,Chamberlain MC.A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas..Cancer2010;116:5297-305

[152] Winkler F,Wick W.Anti-angiogenics: their role in the treatment of glioblastoma..Oncol Res Treat2018;41:181-6

[153] Ellis HP,Powell B,Sottoriva A.Current challenges in glioblastoma: intratumour heterogeneity, residual disease, and models to predict disease recurrence..Front Oncol2015;5:251 PMCID:PMC4644939

[154] Scribner E,Province P,Colin T.Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions..PLoS One2014;9:e115018 PMCID:PMC4266618

[155] Weller M,Perry JR.Standards of care for treatment of recurrent glioblastoma-are we there yet?.Neuro Oncol2013;15:4-27 PMCID:PMC3534423

[156] Wollmann G,van den Pol AN.Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates..Cancer J2012;18:69-81 PMCID:PMC3632333